New Risk • May 19
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹959.8m (US$9.93m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 7.7% per year over the past 5 years. Market cap is less than US$10m (₹959.8m market cap, or US$9.93m). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Reported Earnings • May 17
Full year 2026 earnings released: EPS: ₹3.91 (vs ₹2.46 in FY 2025) Full year 2026 results: EPS: ₹3.91 (up from ₹2.46 in FY 2025). Revenue: ₹1.44b (up 14% from FY 2025). Net income: ₹80.3m (up 59% from FY 2025). Profit margin: 5.6% (up from 4.0% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 8% per year. Announcement • May 11
Archit Organosys Limited to Report Q4, 2026 Results on May 16, 2026 Archit Organosys Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 16, 2026 Valuation Update With 7 Day Price Move • Apr 20
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹49.03, the stock trades at a trailing P/E ratio of 12.5x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 27% over the past three years. New Risk • Feb 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.8% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (₹931.6m market cap, or US$10.3m). Reported Earnings • Feb 09
Third quarter 2026 earnings released: EPS: ₹1.19 (vs ₹0.49 in 3Q 2025) Third quarter 2026 results: EPS: ₹1.19 (up from ₹0.49 in 3Q 2025). Revenue: ₹384.0m (up 48% from 3Q 2025). Net income: ₹24.3m (up 141% from 3Q 2025). Profit margin: 6.3% (up from 3.9% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year whereas the company’s share price has fallen by 17% per year. Announcement • Feb 03
Archit Organosys Limited to Report Q3, 2026 Results on Feb 07, 2026 Archit Organosys Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Feb 07, 2026 Recent Insider Transactions • Dec 12
Chairman recently bought ₹197k worth of stock On the 9th of December, Kandarp Amin bought around 5k shares on-market at roughly ₹39.31 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Kandarp has been a buyer over the last 12 months, purchasing a net total of ₹1.1m worth in shares. New Risk • Nov 25
New major risk - Revenue and earnings growth Earnings have declined by 2.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 2.6% per year over the past 5 years. Market cap is less than US$10m (₹849.1m market cap, or US$9.52m). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. New Risk • Nov 18
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹885.1m (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹885.1m market cap, or US$9.99m). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Announcement • Nov 08
Archit Organosys Limited to Report Q2, 2026 Results on Nov 13, 2025 Archit Organosys Limited announced that they will report Q2, 2026 results on Nov 13, 2025 Announcement • Oct 01
Archit Organosys Limited Approves Dividend Archit Organosys Limited approved dividend recommended by Board of Directors at INR 0.50/- (5%) per equity share of INR 10/- each, at its AGM, held on September 29, 2025. Upcoming Dividend • Sep 15
Upcoming dividend of ₹0.50 per share Eligible shareholders must have bought the stock before 22 September 2025. Payment date: 29 October 2025. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.7%). Announcement • Aug 28
Archit Organosys Limited, Annual General Meeting, Sep 29, 2025 Archit Organosys Limited, Annual General Meeting, Sep 29, 2025. Reported Earnings • Aug 14
First quarter 2026 earnings released: EPS: ₹0.99 (vs ₹0.49 in 1Q 2025) First quarter 2026 results: EPS: ₹0.99 (up from ₹0.49 in 1Q 2025). Revenue: ₹341.9m (up 27% from 1Q 2025). Net income: ₹20.4m (up 102% from 1Q 2025). Profit margin: 6.0% (up from 3.7% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Announcement • Aug 06
Archit Organosys Limited to Report Q1, 2026 Results on Aug 13, 2025 Archit Organosys Limited announced that they will report Q1, 2026 results on Aug 13, 2025 New Risk • May 31
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.2% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (9.3% average weekly change). Market cap is less than US$100m (₹876.4m market cap, or US$10.2m). Reported Earnings • May 24
Full year 2025 earnings released: EPS: ₹2.46 (vs ₹1.60 in FY 2024) Full year 2025 results: EPS: ₹2.46 (up from ₹1.60 in FY 2024). Revenue: ₹1.29b (up 14% from FY 2024). Net income: ₹50.5m (up 54% from FY 2024). Profit margin: 3.9% (up from 2.9% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. New Risk • May 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.8x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₹857.6m market cap, or US$10.0m). Recent Insider Transactions • Apr 03
Whole-Time Director recently bought ₹712k worth of stock On the 28th of March, Archana Amin bought around 19k shares on-market at roughly ₹37.36 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹2.3m more in shares than they have sold in the last 12 months. Valuation Update With 7 Day Price Move • Mar 06
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹45.43, the stock trades at a trailing P/E ratio of 19.6x. Average trailing P/E is 24x in the Chemicals industry in India. Total returns to shareholders of 17% over the past three years. Announcement • Feb 26
Archit Organosys Limited Announces Resignation of Ajay P Patel as Chief Financial Officer, Effective February 28, 2025 Archit Organosys Limited announced that Mr. Ajay P Patel has tendered his resignation from the post of Chief Financial Officer of the company due to personal reasons with effect from close of business hour on February 28, 2025. New Risk • Feb 19
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 2.8x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.8x net interest cover). Market cap is less than US$10m (₹763.6m market cap, or US$8.79m). Minor Risk Large one-off items impacting financial results. Reported Earnings • Feb 16
Third quarter 2025 earnings released: EPS: ₹0.49 (vs ₹0.22 loss in 3Q 2024) Third quarter 2025 results: EPS: ₹0.49 (up from ₹0.22 loss in 3Q 2024). Revenue: ₹268.0m (up 8.0% from 3Q 2024). Net income: ₹10.1m (up ₹14.7m from 3Q 2024). Profit margin: 3.8% (up from net loss in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. New Risk • Jan 27
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹803.6m (US$9.31m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Market cap is less than US$10m (₹803.6m market cap, or US$9.31m). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.9% net profit margin). Recent Insider Transactions • Dec 26
Chairman recently bought ₹684k worth of stock On the 24th of December, Kandarp Amin bought around 16k shares on-market at roughly ₹43.66 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Kandarp's only on-market trade for the last 12 months. New Risk • Nov 25
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 1.1x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.9% net profit margin). Market cap is less than US$100m (₹893.5m market cap, or US$10.6m). Announcement • Oct 01
Archit Organosys Limited Appoints Pruthvik R. Soni as the Company Secretary & Compliance Officer Archit Organosys Limited at its board meeting held on October 1, 2024 approved the appointment of Mr. Pruthvik R. Soni as the Company Secretary & Compliance Officer with immediate effect from October 1, 2024. Announcement • Sep 14
Archit Organosys Limited Announces Resignation of Purvi S. Mitna as Company Secretary Archit Organosys Limited informed that Mrs. Purvi S. Mitna has tendered her resignation from the post of Company Secretary and Compliance Officer of the Company due to personal reasons with effect from close of business hour on 14h September 2024. reason: Resignation due to personal and unavoidable circumstances. Announcement • Aug 20
Archit Organosys Limited, Annual General Meeting, Sep 09, 2024 Archit Organosys Limited, Annual General Meeting, Sep 09, 2024, at 12:30 Indian Standard Time. Reported Earnings • Aug 13
First quarter 2025 earnings released: EPS: ₹0.49 (vs ₹0.77 in 1Q 2024) First quarter 2025 results: EPS: ₹0.49 (down from ₹0.77 in 1Q 2024). Revenue: ₹270.0m (down 13% from 1Q 2024). Net income: ₹10.1m (down 36% from 1Q 2024). Profit margin: 3.7% (down from 5.1% in 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Announcement • Aug 02
Archit Organosys Limited to Report Q1, 2025 Results on Aug 08, 2024 Archit Organosys Limited announced that they will report Q1, 2025 results on Aug 08, 2024 Announcement • Jun 29
Archit Organosys Limited Appoints Purvi S. Mitna as the Company Secretary & Compliance Officer Archit Organosys Limited at its board meeting held on 29 June 2024, approved appointment of Ms. Purvi S. Mitna as the Company Secretary & Compliance Officer with immediate effect i.e., from 29 June 2024. Recent Insider Transactions • Jun 25
Whole Time Director recently bought ₹796k worth of stock On the 20th of June, Archit Amin bought around 15k shares on-market at roughly ₹54.93 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹1.6m more in shares than they have sold in the last 12 months. Valuation Update With 7 Day Price Move • Jun 14
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₹53.31, the stock trades at a trailing P/E ratio of 33.4x. Average trailing P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 18% over the past three years. Reported Earnings • Jun 04
Full year 2024 earnings released: EPS: ₹1.60 (vs ₹5.53 in FY 2023) Full year 2024 results: EPS: ₹1.60 (down from ₹5.53 in FY 2023). Revenue: ₹1.16b (down 9.5% from FY 2023). Net income: ₹32.8m (down 71% from FY 2023). Profit margin: 2.8% (down from 8.9% in FY 2023). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. New Risk • May 31
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹831.3m (US$9.96m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.2x net interest cover). Market cap is less than US$10m (₹831.3m market cap, or US$9.96m). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (2.7% net profit margin). Announcement • May 24
Archit Organosys Limited to Report Q4, 2024 Results on May 30, 2024 Archit Organosys Limited announced that they will report Q4, 2024 results on May 30, 2024 Valuation Update With 7 Day Price Move • Apr 01
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹45.81, the stock trades at a trailing P/E ratio of 27.5x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 91% over the past three years. Announcement • Mar 29
Kandarp Amin, Archana Amin, Archit Amin and Suchit Amin agreed to acquire 50.01% stake in Novel and Nano Xtreme Solutions LLP from Archit Organosys Limited (BSE:524640) for INR 0.5 million. Kandarp Amin, Archana Amin, Archit Amin and Suchit Amin agreed to acquire 50.01% stake in Novel and Nano Xtreme Solutions LLP from Archit Organosys Limited (BSE:524640) for INR 0.5 million on March 27, 2024. The consideration consists of INR 0.501 million in cash. The transaction has been approved by the Board of Directors of Archit Organosys Limited. The expected date of completion of sale will be on or before March 27, 2024. Buy Or Sell Opportunity • Mar 22
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 31% to ₹38.79. The fair value is estimated to be ₹48.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.0% over the last 3 years, while earnings per share has been flat. New Risk • Mar 13
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹815.1m (US$9.84m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.2x net interest cover). Market cap is less than US$10m (₹815.1m market cap, or US$9.84m). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (2.7% net profit margin). Reported Earnings • Feb 15
Third quarter 2024 earnings released: ₹0.22 loss per share (vs ₹1.09 profit in 3Q 2023) Third quarter 2024 results: ₹0.22 loss per share (down from ₹1.09 profit in 3Q 2023). Revenue: ₹253.4m (up 13% from 3Q 2023). Net loss: ₹4.56m (down 120% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Nov 11
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.8% Last year net profit margin: 8.9% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks High level of debt (45% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.8% net profit margin). Market cap is less than US$100m (₹1.06b market cap, or US$12.7m). Announcement • Sep 01
Archit Organosys Limited Declares Dividend Archit Organosys Limited announced that at the AGM was held on August 31, 2023, the company approved dividend of INR 0.50/- (5%) per equity share of INR 10/- each. New Risk • Aug 17
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks High level of debt (42% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Market cap is less than US$100m (₹1.01b market cap, or US$12.1m). Reported Earnings • Aug 15
Full year 2023 earnings released: EPS: ₹5.53 (vs ₹4.01 in FY 2022) Full year 2023 results: EPS: ₹5.53 (up from ₹4.01 in FY 2022). Revenue: ₹1.28b (down 6.5% from FY 2022). Net income: ₹113.5m (up 38% from FY 2022). Profit margin: 8.9% (up from 6.0% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has increased by 78% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Aug 11
Upcoming dividend of ₹0.50 per share at 1.0% yield Eligible shareholders must have bought the stock before 18 August 2023. Payment date: 30 September 2023. Payout ratio is a comfortable 9.0% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of Indian dividend payers (1.4%). Higher than average of industry peers (0.9%). Announcement • Aug 10
Archit Organosys Limited Proposes Declare Archit Organosys Limited at the AGM, the shareholders proposed to declare dividend recommended by the Board of Directors at INR 0.50 (5%) per equity share of INR 10 each. Announcement • Aug 06
Archit Organosys Limited to Report Q1, 2024 Results on Aug 14, 2023 Archit Organosys Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹56.37, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 479% over the past three years. Upcoming Dividend • Aug 01
Upcoming dividend of ₹0.50 per share at 0.9% yield Eligible shareholders must have bought the stock before 08 August 2023. Payment date: 21 September 2023. Payout ratio is a comfortable 9.0% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of Indian dividend payers (1.5%). In line with average of industry peers (0.9%). Announcement • Jul 25
Archit Organosys Limited, Annual General Meeting, Aug 22, 2023 Archit Organosys Limited, Annual General Meeting, Aug 22, 2023, at 12:30 Indian Standard Time. Reported Earnings • May 15
Full year 2023 earnings released: EPS: ₹5.53 (vs ₹4.01 in FY 2022) Full year 2023 results: EPS: ₹5.53 (up from ₹4.01 in FY 2022). Revenue: ₹1.30b (down 5.1% from FY 2022). Net income: ₹113.5m (up 38% from FY 2022). Profit margin: 8.8% (up from 6.0% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has increased by 124% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 13
Archit Organosys Limited Recommends a Final Dividend for the Financial Year Ended March 31, 2023 Archit Organosys Limited at its board meeting held on May 12, 2023, recommended a final dividend of INR 0.50 per equity share (5%) of INR 10/- each for the financial year ended March 31, 2023. The dividend, if declared by the shareholders in the upcoming 30th Annual General Meeting of the Company shall be paid to the shareholders within 30 days from the date of Annual General Meeting. Recent Insider Transactions • Mar 08
Chairman & Whole Time Director recently bought ₹507k worth of stock On the 3rd of March, Kandarpbhai Amin bought around 7k shares on-market at roughly ₹71.24 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹1.9m. Kandarpbhai has been a buyer over the last 12 months, purchasing a net total of ₹3.8m worth in shares. Recent Insider Transactions • Feb 02
Chairman & Whole Time Director recently bought ₹1.3m worth of stock On the 31st of January, Kandarpbhai Amin bought around 20k shares on-market at roughly ₹67.50 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Kandarpbhai's only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Jan 20
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹77.50, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 780% over the past three years. Reported Earnings • Jan 14
Third quarter 2023 earnings released: EPS: ₹1.09 (vs ₹0.99 in 3Q 2022) Third quarter 2023 results: EPS: ₹1.09 (up from ₹0.99 in 3Q 2022). Revenue: ₹226.2m (down 42% from 3Q 2022). Net income: ₹22.3m (up 10.0% from 3Q 2022). Profit margin: 9.9% (up from 5.2% in 3Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has increased by 102% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jan 05
Archit Organosys Limited to Report Q3, 2023 Results on Jan 13, 2023 Archit Organosys Limited announced that they will report Q3, 2023 results on Jan 13, 2023 Valuation Update With 7 Day Price Move • Dec 07
Investor sentiment improved over the past week After last week's 32% share price gain to ₹94.75, the stock trades at a trailing P/E ratio of 17.5x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 1,189% over the past three years. Reported Earnings • Nov 16
Second quarter 2023 earnings released: EPS: ₹1.49 (vs ₹0.68 in 2Q 2022) Second quarter 2023 results: EPS: ₹1.49 (up from ₹0.68 in 2Q 2022). Revenue: ₹286.3m (down 33% from 2Q 2022). Net income: ₹30.6m (up 118% from 2Q 2022). Profit margin: 11% (up from 3.3% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Nov 13
Second quarter 2023 earnings released: EPS: ₹1.49 (vs ₹0.68 in 2Q 2022) Second quarter 2023 results: EPS: ₹1.49 (up from ₹0.68 in 2Q 2022). Revenue: ₹286.3m (down 33% from 2Q 2022). Net income: ₹30.6m (up 118% from 2Q 2022). Profit margin: 11% (up from 3.3% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Nov 03
Archit Organosys Limited to Report Q2, 2023 Results on Nov 11, 2022 Archit Organosys Limited announced that they will report Q2, 2023 results on Nov 11, 2022 Announcement • Oct 11
Archit Organosys Limited Announces Chief Financial Officer Changes Archit Organosys Limited Board of Directors has at its meeting held on 10 October 2022, approved the appointment Company has at its meeting held of Mr. Ajay Punamchand Patel as Chief 'Financial officer (Key managerial Personnel) with effect from 10 October, 2022. in place of Mr. Gajendrasingh Rajput who has expressed his intention to resign due to personal reason from the event date. Mr. Ajay Punamchand Patel has bright academic background and is proficient in various area of Accounting and Financial field such as Auditing, Fund Management and Direct and Indirect Taxation and having experience of more than 5 years. Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improved over the past week After last week's 16% share price gain to ₹79.05, the stock trades at a trailing P/E ratio of 17.2x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 846% over the past three years. Announcement • Sep 09
Archit Organosys Limited Approves Dividend Archit Organosys Limited announced that at the AGM held on September 8, 2022 approved dividend of INR 0.75 per equity share of INR 10 each. Valuation Update With 7 Day Price Move • Aug 18
Investor sentiment improved over the past week After last week's 26% share price gain to ₹60.55, the stock trades at a trailing P/E ratio of 13.2x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 528% over the past three years. Announcement • Aug 10
Archit Organosys Limited, Annual General Meeting, Sep 08, 2022 Archit Organosys Limited, Annual General Meeting, Sep 08, 2022, at 12:35 Indian Standard Time. Reported Earnings • Jul 26
First quarter 2023 earnings released: EPS: ₹2.01 (vs ₹1.42 in 1Q 2022) First quarter 2023 results: EPS: ₹2.01 (up from ₹1.42 in 1Q 2022). Revenue: ₹305.6m (up 6.6% from 1Q 2022). Net income: ₹41.2m (up 41% from 1Q 2022). Profit margin: 14% (up from 10% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has only increased by 81% per year, which means it is significantly lagging earnings growth. Announcement • Jul 19
Archit Organosys Limited to Report Q1, 2023 Results on Jul 25, 2022 Archit Organosys Limited announced that they will report Q1, 2023 results on Jul 25, 2022 Announcement • May 14
Archit Organosys Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022 Archit Organosys Limited announced that the Board of Directors of the Company at their meeting held on 12 May 2022, Recommended a final dividend of INR 0.75 per equity share (INR 7.50%) of INR 10 each for the financial year ended March 31, 2022. The dividend, if declared by the shareholders in the upcoming 29th Annual of the Company shall be days from the date of Annual General Meeting paid to the shareholders within 30 General Meeting. Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improved over the past week After last week's 16% share price gain to ₹43.50, the stock trades at a trailing P/E ratio of 11.2x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 249% over the past three years. Announcement • Mar 01
Archit Organosys Limited Announces Appointment of Vijay A. Boliya as Company Secretary and Compliance Officer, Effective March 1, 2022 Archit Organosys Limited, at the board meeting held on 28 February, 2022, approved the appointment of Mr. Vijay A. Boliya as the Company Secretary & Compliance Officer with effect from 01 March, 2022. Reported Earnings • Feb 15
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹0.99 (down from ₹1.02 in 3Q 2021). Revenue: ₹400.4m (up 57% from 3Q 2021). Net income: ₹20.3m (up 33% from 3Q 2021). Profit margin: 5.1% (down from 6.0% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 129% per year but the company’s share price has only increased by 49% per year, which means it is significantly lagging earnings growth. Announcement • Feb 09
Archit Organosys Limited Announces Resignation of Anchal Bansal as Company Secretary and Compliance Officer Archit Organosys Limited announced that Ms. Anchal Bansal has tendered her resignation from the post of Company Secretary and Compliance Officer of the Company due to personal reasons with effect from February 8, 2022. Reported Earnings • Nov 04
Second quarter 2022 earnings released: EPS ₹0.68 (vs ₹0.70 in 2Q 2021) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: ₹431.2m (up 63% from 2Q 2021). Net income: ₹14.1m (up 34% from 2Q 2021). Profit margin: 3.3% (down from 4.0% in 2Q 2021). The decrease in margin was driven by higher expenses. Reported Earnings • Aug 09
First quarter 2022 earnings released: EPS ₹1.42 (vs ₹0.55 in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹286.7m (up 135% from 1Q 2021). Net income: ₹29.2m (up 251% from 1Q 2021). Profit margin: 10% (up from 6.8% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Executive Departure • Jul 20
Independent Director Rajendraprasad Shah has left the company On the 14th of July, Rajendraprasad Shah's tenure as Independent Director ended after 5.0 years in the role. We don't have any record of a personal shareholding under Rajendraprasad's name. Rajendraprasad is the only executive to leave the company over the last 12 months. Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment improved over the past week After last week's 20% share price gain to ₹49.60, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 22% over the past three years. Reported Earnings • Jun 18
Full year 2021 earnings released: EPS ₹3.33 (vs ₹0.53 loss in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹950.5m (up 24% from FY 2020). Net income: ₹50.1m (up ₹58.1m from FY 2020). Profit margin: 5.3% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jun 08
Investor sentiment improved over the past week After last week's 19% share price gain to ₹46.85, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 10% over the past three years. Valuation Update With 7 Day Price Move • May 22
Investor sentiment improved over the past week After last week's 15% share price gain to ₹37.40, the stock trades at a trailing P/E ratio of 19.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 3.9% over the past three years. Valuation Update With 7 Day Price Move • Apr 20
Investor sentiment improved over the past week After last week's 16% share price gain to ₹27.50, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 17x in the Chemicals industry in India. Total loss to shareholders of 33% over the past three years. Reported Earnings • Feb 17
Third quarter 2021 earnings released: EPS ₹1.02 (vs ₹0.37 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹254.3m (up 39% from 3Q 2020). Net income: ₹15.3m (up ₹20.9m from 3Q 2020). Profit margin: 6.0% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Announcement • Feb 06
Archit Organosys Limited to Report Q3, 2021 Results on Feb 13, 2021 Archit Organosys Limited announced that they will report Q3, 2021 results on Feb 13, 2021 Valuation Update With 7 Day Price Move • Feb 06
Investor sentiment improved over the past week After last week's 22% share price gain to ₹25.00, the stock is trading at a trailing P/E ratio of 46.2x, up from the previous P/E ratio of 37.9x. This compares to an average P/E of 18x in the Chemicals industry in India. Total return to shareholders over the past three years is a loss of 52%. Is New 90 Day High Low • Feb 06
New 90-day high: ₹25.00 The company is up 34% from its price of ₹18.70 on 06 November 2020. The Indian market is up 23% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period. Is New 90 Day High Low • Jan 05
New 90-day high: ₹24.55 The company is up 74% from its price of ₹14.14 on 07 October 2020. The Indian market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 21% over the same period. Valuation Update With 7 Day Price Move • Dec 14
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ₹19.30, the stock is trading at a trailing P/E ratio of 35.6x, down from the previous P/E ratio of 43.9x. This compares to an average P/E of 17x in the Chemicals industry in India. Total return to shareholders over the past three years is a loss of 61%. Is New 90 Day High Low • Dec 07
New 90-day high: ₹23.80 The company is up 113% from its price of ₹11.19 on 08 September 2020. The Indian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 16% over the same period. Announcement • Oct 29
Archit Organosys Limited to Report First Half, 2021 Results on Nov 09, 2020 Archit Organosys Limited announced that they will report first half, 2021 results on Nov 09, 2020